This is a mRNA. news story, published by Investor's Business Daily, that relates primarily to Moderna news.
For more mRNA. news, you can click here:
more mRNA. newsFor more Moderna news, you can click here:
more Moderna newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Moderna stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest stock news, Stocks news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Moderna sharesInvestor's Business Daily
•Business
Business & Economics
76% Informative
Moderna (MRNA) stock took a beating in January after the company slashed its outlook for 2024 and 2025 .
William Blair analyst Myles Minter called Moderna stock a "show-me story" The company is working hard to expand its portfolio.
Moderna 's technology focuses on helping the body create specific messenger RNA , or mRNA.
Despite a promising move after the CDC put out Covid test news, Moderna stock isn't a buy. In fact, shares were definitively a sell on Jan. 13 when they tumbled below their 50-day line. It could take several years for Moderna 's pipeline to really pan out, analysts say. In the meantime, its Covid vaccine has yet to hit a bottom and its RSV vaccine is coming from behind in competition with Pfizer and GSK ( GSK ). Follow Allison Gatlin on X/Twitter at @IBD_AGatlin. YOU MAY ALSO LIKE:.
VR Score
79
Informative language
82
Neutral language
25
Article tone
formal
Language
English
Language complexity
42
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Source diversity
3
Affiliate links
no affiliate links
